Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PPARgamma, an X-ceptor for Xs.

Hana Koutnikova1, Johan Auwerx

  • 1Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), CNRS/INSERM/Université Louis Pasteur, F-67404 Illkirch, France.

Annals of the New York Academy of Sciences
|June 25, 2002
PubMed
Summary

Peroxisome proliferator-activated receptor gamma (PPARgamma) plays a role in fat formation and metabolic disorders. A new compound, FMOC-l-leucine (FLL), shows potential for therapeutic benefits by modulating PPARgamma, offering improved insulin sensitization with less adipogenesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temperature determines early-life success of burbot Lota lota eggs.

Journal of fish biology·2026
Same author

Western diet-induced MASH in PWK/PhJ mice identifies disruptions in amino acid and sphingolipid metabolism contributing to cardiac dysfunction.

Nature communications·2026
Same author

Endometrial NCOR1 deficiency contributes to implantation failure in endometriosis-associated infertility.

iScience·2026
Same author

The PM20D1-OLE pathway induces microglia rewiring to ameliorate Alzheimer disease.

Cell death & disease·2026
Same author

Dynamics of genetic and somatic trade-offs in ageing and mortality.

Nature·2026
Same author

How to train your rodent: Recommendations for the preclinical study of exercise-induced benefits in metabolic research.

Cell metabolism·2026

Area of Science:

  • Metabolic disease research
  • Molecular pharmacology
  • Endocrinology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARgamma) is implicated in fat formation and insulin sensitization.
  • Its role in metabolic disorders like obesity and type 2 diabetes suggests potential drawbacks of full activation.
  • The
  • thrifty gene
  • hypothesis links PPARgamma to evolutionary adaptation and modern
  • times of plenty
  • pathogenesis.

Purpose of the Study:

  • To investigate a new chemical class of PPARgamma agonists, FMOC-l-leucine (FLL).
  • To compare the mechanism and efficacy of FLL with existing PPARgamma ligands.
  • To explore the therapeutic potential of PPARgamma modulation versus activation.

Related Experiment Videos

Main Methods:

  • Characterization of FLL as a novel PPARgamma agonist.
  • Mass spectrometry to determine FLL's binding mode to PPARgamma.
  • Assessment of coactivator recruitment, receptor activation, adipogenic activity, and insulin sensitization.

Main Results:

  • FLL induces a distinct PPARgamma conformation with a unique binding mode (2:1 FLL:PPARgamma).
  • FLL exhibits lower potency but similar maximal efficacy compared to classical ligands, with significantly weaker adipogenic activity.
  • FLL demonstrates superior insulin sensitization compared to current PPARgamma agonists.

Conclusions:

  • FLL represents a new class of PPARgamma modulators with distinct properties.
  • The findings support the therapeutic potential of PPARgamma modulation over full activation for metabolic diseases.
  • FLL's improved insulin sensitization with reduced adipogenesis offers a promising therapeutic avenue.